 Both the HEPT and TIBO compounds were first to be identified as highly specific and potent HIV-1 RT inhibitors, not active against other RTs.These compounds do not interrupt the cellular or mitochondrial DNA synthesis.The specificity of the NNRTIs for HIV-1 is considered the hallmark of the NNRTI drug class.